K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
$93.95
Prev. Close
$92.11
Prev. Day's Range
$91.64 - $94.10
52W Range
$81.97 - $135.34
Trading Volume
9.111M
MC
$163.609B
P/E Ratio
26.3x
EPS
$3.57
Company Overview
NYSE
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
SectorHEALTHCARE
IndustryMEDICAL DEVICES
Headquarters100 ABBOTT PARK ROAD, ABBOTT PARK, IL, UNITED STATES, 60064-6400
Abbott Laboratories (ABT) operates in the healthcare sector, specializing in medical devices, diagnostics, nutritional products, and pharmaceuticals. The company is known for producing innovations such as its glucose monitoring system, FreeStyle Libre, as well as diagnostic tools and infant nutrition products. Its diversified business model allows for stable revenue across multiple healthcare segments.
Abbott Laboratories generates revenue primarily from its medical devices, diagnostics, and nutritional products. Flagship offerings like FreeStyle Libre for diabetes management and its laboratory diagnostic solutions contribute significantly to sales. The company also benefits from global demand for pediatric and adult nutrition and pharmaceutical products in select markets.
Abbott Laboratories faces competition from companies like Medtronic, Johnson & Johnson, and Roche in the medical devices and diagnostics sectors. Abbott differentiates itself with innovative technologies like FreeStyle Libre and its broad product portfolio, which spans multiple healthcare markets. However, competition remains intense, particularly in fast-growing areas like diabetes care and diagnostics.
Investors in Abbott Laboratories should consider risks such as regulatory hurdles, competition in the healthcare market, and currency fluctuations that could affect international revenue. Additionally, pricing pressures in healthcare and disruptions to its international supply chains may also impact financial performance. Diversification mitigates some risks but does not eliminate them entirely.
Yes, Abbott Laboratories pays a dividend to its shareholders. The company has a long history of dividend payments and is considered a Dividend Aristocrat, having consistently increased its dividend payouts for several consecutive years. Investors often view Abbott as a stable option for income-focused investing.
Abbott Laboratories maintains growth by innovating in high-demand areas like diabetes care and diagnostics, as well as expanding its global market reach. Its strong research and development efforts allow the company to bring competitive products to market. Additionally, growth in emerging markets helps to bolster its revenue streams.
Abbott Laboratories has significant growth opportunities in areas like diabetes care, with its FreeStyle Libre system, and laboratory diagnostics. The aging global population and increasing focus on preventive healthcare are expected to drive demand for Abbott’s products. Expanding in emerging markets could also provide substantial long-term growth potential.
Abbott Laboratories’ financial stability is supported by its diversified revenue streams across medical devices, diagnostics, nutrition, and pharmaceuticals. Its strong global presence, consistent cash flow, and history of profitability further add to its resilience. The company’s commitment to innovation also helps maintain its competitive advantage in the healthcare market.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.
